Abstract:Background: Primary biliary cholangitis (PBC) is characterized by nonsuppurative destructive cholangitis and is thought to be an autoimmune disorder. Currently, ursodeoxycholic acid (UDCA) is the only FDA approved first line therapy for PBC, but up to nearly one-third of patients do not achieve a complete response to this treatment. Adaptive immune cells, including T cells and B cells, have been found in the portal tracts and the bile duct epithelium and play a role in the pathogenesis of PBC, but the importance of these cells for evaluating the therapeutic response to UDCA in PBC has not yet been studied. Methods: In this study, we collected liver puncture biopsy specimens from 34 matched patients with PBC before and after UDCA treatment and investigated the relationship between the infiltration of adaptive immune cells and the treatment response to UDCA. The extent of immune cell infiltration was determined by immunohistochemical analysis. Responses were defined based on Paris-I criteria Results: After 1 year of treatment, 25/34 patients responded to UDCA treatment according to Paris-I criteria (responders), and 9/34 patients were nonresponders. Immunohistochemical analysis showed that UDCA responders exhibited significantly less CD4+ T cell infiltration after UDCA treatment than before (50.4 7.5/HPF vs 30.0 +/- 7.9/HPF, P = 0.002). In contrast, UDCA nonresponders exhibited significantly more CD4+ T cell infiltration after UDCA treatment than before (32.2 +/- 8.0/HPF vs 75.0 +/- 13.9/HPF, P = 0.045). Moreover, patients who exhibited a reduction in CD4+ T cell infiltration after UDCA treatment had a higher response rate than those that exhibited an increase in CD4+ T cell infiltration (85.7 % vs 53.8 %, P = 0.041). However, CD3+ T cell, CD8+ T cell, and CD20+ B cell infiltration was not significantly different before and after treatment in either UDCA responders or nonresponders. Furthermore, we found that the number of infiltrating T-bet+ Th1 cells was much lower after UDCA treatment than before in responders (10.5 +/- 5.7/HPF vs. 5.16 +/- 4.0/HPF, P = 0.0214) but much higher in nonresponders after treatment than before (1.89 +/- 1.2/HPF vs. 12.3 +/- 5.4/HPF, P = 0.043). However, there was no difference in the extent of GATA3+ Th2 or FOXP3+ Treg infiltration before and after treatment in either UDCA responders or nonresponders. Conclusion: Collectively, our results suggest that a decrease in the number of liver-infiltrating CD4+ Th1 cells is associated with a good response of PBC patients to UDCA treatment. Immunohistochemical analysis of CD4 and T-bet in PBC liver specimens may be a potential approach for evaluating the therapeutic response to UDCA.

Biochemical and Immunologic Effects of Rituximab in Patients with Primary Biliary Cirrhosis and an Incomplete Response to Ursodeoxycholic Acid.

Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20 + B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study

Evidence for the Association Between IgG‐antimitochondrial Antibody and Biochemical Response to Ursodeoxycholic Acid Treatment in Primary Biliary Cholangitis

Rituximab-bortezomib-dexamethasone Induce High Response Rates in Imcd in Clinical Practice.

P1313: LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis

Decreased Infiltration of CD4+ Th1 Cells Indicates a Good Response to Ursodeoxycholic Acid (UDCA) in Primary Biliary Cholangitis.

Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune Diseases

B cell depletion therapy exacerbates murine primary biliary cirrhosis

[Rituximab Treatment for Adults with Steroid-Resistant Idiopathic Thrombocytopenic Purpura].

Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma

Rituximab, Use and B Cell Depletion in Patients with Membranous Nephropathy- A Retrospective, Observational Study

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases

[Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia]

Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy

Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission

B-cells depletion after treatment with rituximab predicts relapse of IgG4-related disease